Related Experiment Video
Updated: May 16, 2026

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
Published on: June 30, 2023
ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation
Guoliang Qing1, Bo Li, Annette Vu
1Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
Oncogenic Myc alters mitochondrial metabolism, making it dependent on exogenous glutamine (Gln) for cell survival. Accordingly, Gln deprivation selectively induces apoptosis in MYC-overexpressing cells via unknown mechanisms. Using MYCN-amplified neuroblastoma as a model, we identify PUMA, NOXA, and TRB3 as executors of Gln-starved cells. Gln depletion in MYC-transformed cells induces apoptosis through ATF4-dependent, but p53-independent, PUMA and NOXA induction. MYC-transformed cells depend on both glutamate-oxaloacetate transaminase and glutamate dehydrogenase to maintain Gln homeostasis and suppress apoptosis. Consequently, either ATF4 agonists or glutaminolysis inhibitors potently induce apoptosis in vitro and inhibit tumor growth in vivo. These results reveal mechanisms whereby Myc sensitizes cells to apoptosis, and validate ATF4 agonists and inhibitors of Gln metabolism as potential Myc-selective cancer therapeutics.
Insights
Oncogenic Myc drives cancer cell dependence on glutamine (Gln). Gln deprivation triggers apoptosis in Myc-overexpressing cells by inducing PUMA and NOXA via ATF4, offering new therapeutic targets.
Area of Science:
- Cancer Biology
- Metabolic Regulation
- Molecular Oncology
Background:
- Oncogenic Myc proteins reprogram cellular metabolism, creating a dependency on exogenous glutamine (Gln) for survival.
- Glutamine deprivation selectively induces apoptosis in Myc-overexpressing cancer cells through incompletely understood mechanisms.
Purpose of the Study:
- To elucidate the molecular mechanisms by which glutamine deprivation induces apoptosis in Myc-transformed cells, using MYCN-amplified neuroblastoma as a model.
- To identify potential therapeutic strategies targeting Myc-driven cancers by exploiting their metabolic vulnerabilities.
Main Methods:
- Utilized MYCN-amplified neuroblastoma cell models.
- Investigated the roles of apoptosis executors PUMA, NOXA, and TRB3.
- Analyzed the involvement of the ATF4 transcription factor and p53.
- Assessed the contribution of glutamate-oxaloacetate transaminase and glutamate dehydrogenase in Gln homeostasis.
- Evaluated the efficacy of ATF4 agonists and glutaminolysis inhibitors in vitro and in vivo.
Main Results:
- Identified PUMA, NOXA, and TRB3 as key mediators of apoptosis in Gln-starved Myc-transformed cells.
- Demonstrated that Gln depletion induces apoptosis via ATF4-dependent, p53-independent upregulation of PUMA and NOXA.
- Showed that MYC-transformed cells rely on glutamate-oxaloacetate transaminase and glutamate dehydrogenase for Gln metabolism and survival.
- Confirmed that ATF4 agonists and glutaminolysis inhibitors effectively induce apoptosis and inhibit tumor growth.
Conclusions:
- Myc sensitizes cancer cells to apoptosis upon glutamine deprivation through specific molecular pathways involving ATF4, PUMA, and NOXA.
- Targeting ATF4 or glutaminolysis represents a promising therapeutic approach for Myc-driven cancers, including neuroblastoma.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
